Young Chang

Young Chang

Auto-generated profile, based on publicly available information

Young Chang

Department of Internal Medicine, Institute for Digestive Research, Digestive Disease Center, Soonchunhyang University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2020 in Gut
Verified
Journal Article
Closed access
PDF file
MKMinseok Albert Kim
Minseok Albert Kim
Seung Up KimSeung Up Kim
Seung Up Kim
DSDong Hyun Sinn
Dong Hyun Sinn
Jeong Won JangJeong Won Jang
Jeong Won Jang
YLYoung-Suk Lim
Young-Suk Lim
JLJeong-Hoon Lee
Jeong-Hoon Lee
Objective Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether NA discontinuation was as safe as NA continuation after NA-induced surface antigen of HBV (HBsAg) seroclearance was investigated in the present study. Designs This multicentre study included 276 patients from 16 hospitals in Korea who achieved NA-induced HBsAg seroclearance: 131 (47.5%) discontinued NA treatment within 6 months after HBsAg seroclearance (NA discontinuation group) and 145 (52.5%) continued NA treatment (NA continuation group). Primary endpoint was HBsAg reversion and secondary endpoints included serum HBV DNA redetection and development of hepatocellular carcinoma (HCC). Results During follow-up (median=26.9 months, IQR=12.2–49.2 months), 10 patients (3.6%) experienced HBsAg reversion, 6 (2.2%) showed HBV DNA redetection and 8 (2.9%) developed HCC. Compared with NA continuation, NA discontinuation was not associated with HBsAg reversion in both univariable (HR=0.45, 95% CI=0.12 to 1.76, log-rank p=0.24) and multivariable analyses (adjusted HR=0.65, 95% CI=0.16 to 2.59, p=0.54). The cumulative probabilities of HBsAg reversion at 1, 3 and 5 years were 0.8%, 2.3% and 5.0% in the NA discontinuation group, and 1.5%, 6.3% and 8.4% in the NA continuation group, respectively. NA discontinuation was not associated with higher risk of either HBV redetection (HR=0.83, 95% CI=0.16 to 4.16, log-rank p=0.82) or HCC development (HR=0.53, 95% CI=0.12 to 2.23, log-rank p=0.38). Conclusion The discontinuation of NA was not associated with a higher risk of either HBsAg reversion, serum HBV DNA redetection or HCC development compared with NA continuation among patients who achieved HBsAg seroclearance with NA.

2 April 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
HKHwi Young Kim
Hwi Young Kim
JNJ. Y. Nam
J. Y. Nam
JLJeong-Hoon Lee
Jeong-Hoon Lee
HLHye Ah Lee
Hye Ah Lee
YCY. Chang
Y. Chang
JYJung-Hwan Yoon
Jung-Hwan Yoon

3 March 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
JYJun Sik Yoon
Jun Sik Yoon
HLHyo Young Lee
Hyo Young Lee
SCSung Won Chung
Sung Won Chung
SKSun Woong Kim
Sun Woong Kim
YCYoung Chang
Young Chang
YKYoon Jun Kim
Yoon Jun Kim

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
LKLog Young Kim
Log Young Kim
JYJeong-Ju Yoo
Jeong-Ju Yoo
YCYoung Chang
Young Chang
HJHoongil Jo
Hoongil Jo
YCYoung Youn Cho
Young Youn Cho
TLthe Korean Association for the Study of the Liver
the Korean Association for the Study of the Liver
Kim LY, et al. J Korean Med Sci. 2023 Dec;39(4):e22. https://doi.org/10.3346/jkms.2024.39.e22

31 March 2025 in Journal of Liver Cancer
Verified
Journal Article
Open access
PDF file
JAJihyun An
Jihyun An
YCYoung Chang
Young Chang
GCGwang Hyeon Choi
Gwang Hyeon Choi
WSWon Sohn
Won Sohn
JSJeong Eun Song
Jeong Eun Song
BKBo Hyun Kim
Bo Hyun Kim
Backgrounds/Aims: Hepatocellular carcinoma (HCC) is the sixth most common cancer and second leading cause of cancer-related deaths in South Korea. This study evaluated the characteristics of Korean patients newly diagnosed with HCC in 2016-2018.Methods: Data from the Korean Primary Liver Cancer Registry (KPLCR), a representative database of patients newly diagnosed with HCC in South Korea, were analyzed. This study investigated 4,462 patients with HCC registered in the KPLCR in 2016-2018.Results: The median patient age was 63 years (interquartile range, 55-72). 79.7% of patients were male. Hepatitis B infection was the most common underlying liver disease (54.5%). The Barcelona Clinic Liver Cancer (BCLC) staging system classified patients as follows: stage 0 (14.9%), A (28.8%), B (7.5%), C (39.0%), and D (9.8%). The median overall survival was 3.72 years (95% confidence interval, 3.47-4.14), with 1-, 3-, and 5-year overall survival rates of 71.3%, 54.1%, and 44.3%, respectively. In 2016-2018, there was a significant shift toward BCLC stage 0-A and Child-Turcotte-Pugh liver function class A (P<0.05), although survival rates did not differ by diagnosis year. In the treatment group (n=4,389), the most common initial treatments were transarterial therapy (31.7%), surgical resection (24.9%), best supportive care (18.9%), and local ablation therapy (10.5%).Conclusions: Between 2016 and 2018, HCC tended to be diagnosed at earlier stages, with better liver function in later years. However, since approximately half of the patients remained diagnosed at an advanced stage, more rigorous and optimized HCC screening strategies should be implemented.

6 December 2005 in Digestive Endoscopy
Verified
Journal Article
Closed access
PDF file
YCYoung Woon Chang
Young Woon Chang